Structure-Based Design of [gamma]-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors

Ran, Xu; Zhao, Yujun; Liu, Liu; Bai, Longchuan; Yang, Chao-Yie; Zhou, Bing; Meagher, Jennifer L.; Chinnaswamy, Krishnapriya; Stuckey, Jeanne A.; Wang, Shaomeng

doi:10.1021/acs.jmedchem.5b00613

Title: Structure-Based Design of [gamma]-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors

Full Record
Other Related Research

Authors:

Ran, Xu; Zhao, Yujun; Liu, Liu; Bai, Longchuan; Yang, Chao-Yie; Zhou, Bing; Meagher, Jennifer L.; Chinnaswamy, Krishnapriya; Stuckey, Jeanne A.; Wang, Shaomeng ^[1]

Michigan

Publication Date:: Fri Oct 23 00:00:00 EDT 2015

Research Org.:: Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)

Sponsoring Org.:: NIHOTHER

OSTI Identifier:: 1214846

Resource Type:: Journal Article

Journal Name:: J. Med. Chem.

Additional Journal Information:: Journal Volume: 58; Journal Issue: (12) ; 06, 2015

Country of Publication:: United States

Language:: ENGLISH

Citation Formats


                    Ran, Xu, Zhao, Yujun, Liu, Liu, Bai, Longchuan, Yang, Chao-Yie, Zhou, Bing, Meagher, Jennifer L., Chinnaswamy, Krishnapriya, Stuckey, Jeanne A., and Wang, Shaomeng. Structure-Based Design of [gamma]-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.  United States: N. p., 2015. 
        Web.  doi:10.1021/acs.jmedchem.5b00613.

Copy to clipboard


                    Ran, Xu, Zhao, Yujun, Liu, Liu, Bai, Longchuan, Yang, Chao-Yie, Zhou, Bing, Meagher, Jennifer L., Chinnaswamy, Krishnapriya, Stuckey, Jeanne A., & Wang, Shaomeng. Structure-Based Design of [gamma]-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.  United States.  https://doi.org/10.1021/acs.jmedchem.5b00613

Copy to clipboard


                    Ran, Xu, Zhao, Yujun, Liu, Liu, Bai, Longchuan, Yang, Chao-Yie, Zhou, Bing, Meagher, Jennifer L., Chinnaswamy, Krishnapriya, Stuckey, Jeanne A., and Wang, Shaomeng. 2015.  
        "Structure-Based Design of [gamma]-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors".  United States.  https://doi.org/10.1021/acs.jmedchem.5b00613.

Copy to clipboard


                    
@article{osti_1214846,

  title        = {Structure-Based Design of [gamma]-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors},

  author       = {Ran, Xu and Zhao, Yujun and Liu, Liu and Bai, Longchuan and Yang, Chao-Yie and Zhou, Bing and Meagher, Jennifer L. and Chinnaswamy, Krishnapriya and Stuckey, Jeanne A. and Wang, Shaomeng},

  abstractNote = {},

  doi          = {10.1021/acs.jmedchem.5b00613},

  url          = {https://www.osti.gov/biblio/1214846},
  journal      = {J. Med. Chem.},
number       = (12) ; 06, 2015,

  volume       = 58,

  place        = {United States},

  year         = {Fri Oct 23 00:00:00 EDT 2015},

  month        = {Fri Oct 23 00:00:00 EDT 2015}

}

Copy to clipboard

Journal Article:

https://doi.org/10.1021/acs.jmedchem.5b00613

Other availability

Find in Google Scholar

Search WorldCat to find libraries that may hold this journal

Save / Share:

Export Metadata

Save to My Library

Similar records in OSTI.GOV collections:

Structure-Based Discovery of CF53 as a Potent and Orally Bioavailable Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitor

Journal Article Zhao, Yujun; Zhou, Bing; Bai, Longchuan; ... - Journal of Medicinal Chemistry

We report the structure-based discovery of CF53 (28) as a highly potent and orally active inhibitor of bromodomain and extra-terminal (BET) proteins. By the incorporation of a NH-pyrazole group into the 9H-pyrimido[4,5-b]indole core, we identified a series of compounds that bind to BRD4 BD1 protein with K_i values of <1 nM and achieve low nanomolar potencies in the cell growth inhibition of leukemia and breast cancer cells. The most-promising compound, CF53, possesses excellent oral pharmacokinetic properties and achieves significant antitumor activity in both triple-negative breast cancer and acute leukemia xenograft models in mice. Determination of the co-crystal structure of CF53more »« less
Cited by 20
https://doi.org/10.1021/acs.jmedchem.8b00483

Full Text Available
Fragment-Based, Structure-Enabled Discovery of Novel Pyridones and Pyridone Macrocycles as Potent Bromodomain and Extra-Terminal Domain (BET) Family Bromodomain Inhibitors

Journal Article Wang, Le; Pratt, John; Soltwedel, Todd; ... - Journal of Medicinal Chemistry

Members of the BET family of bromodomain containing proteins have been identified as potential targets for blocking proliferation in a variety of cancer cell lines. A two-dimensional NMR fragment screen for binders to the bromodomains of BRD4 identified a phenylpyridazinone fragment with a weak binding affinity (1, Ki = 160 μM). SAR investigation of fragment 1, aided by X-ray structure-based design, enabled the synthesis of potent pyridone and macrocyclic pyridone inhibitors exhibiting single digit nanomolar potency in both biochemical and cell based assays. Advanced analogs in these series exhibited high oral exposures in rodent PK studies and demonstrated significant tumormore »« less
https://doi.org/10.1021/acs.jmedchem.7b00017
Structure-Guided Design of Potent Diazobenzene Inhibitors for the BET Bromodomains

Journal Article Zhang, G.; Plotnikov, A.; Rusinova, E.; ... - Journal of Medicinal Chemistry
https://doi.org/10.1021/jm401334s
Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9 H -pyrimido[4,5- b ]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor

Journal Article Zhao, Yujun; Bai, Longchuan; Liu, Liu; ... - Journal of Medicinal Chemistry

We have designed and synthesized 9H-pyrimido[4,5-b]indole-containing compounds to obtain potent and orally bioavailable BET inhibitors. By incorporation of an indole or a quinoline moiety to the 9H-pyrimido[4,5-b]indole core, we identified a series of small molecules showing high binding affinities to BET proteins and low nanomolar potencies in inhibition of cell growth in acute leukemia cell lines. One such compound, 4-(6-methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (31) has excellent microsomal stability and good oral pharmacokinetics in rats and mice. Orally administered, 31 achieves significant antitumor activity in the MV4;11 leukemia and MDA-MB-231 triple-negative breast cancer xenograft models in mice. Determination of the cocrystal structure of 31more »« less
Cited by 34
https://doi.org/10.1021/acs.jmedchem.7b00193

Full Text Available
Discovery of N -(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1 H -pyrrolo[2,3- c ]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor

Journal Article McDaniel, Keith; Wang, Le; Soltwedel, Todd; ... - Journal of Medicinal Chemistry
https://doi.org/10.1021/acs.jmedchem.7b00746

Similar Records